Test Code IMMAU Inborn Errors of Immunity with Immune Dysregulation and Autoimmunity Gene Panel, Varies
Ordering Guidance
Targeted testing for familial variants (also called site-specific or known variants testing) is available for the genes on this panel. See FMTT / Familial Variant, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.
Shipping Instructions
Specimen preferred to arrive within 96 hours of collection.
Specimen Required
Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.
Submit only 1 of the following specimens:
Specimen Type: Whole blood
Container/Tube:
Preferred: Lavender top (EDTA) or yellow top (ACD)
Acceptable: Any anticoagulant
Specimen Volume: 3 mL
Collection Instructions:
1. Invert several times to mix blood.
2. Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated
Specimen Type: Skin biopsy
Supplies: Fibroblast Biopsy Transport Media (T115)
Container/Tube: Sterile container with any standard cell culture media (eg, minimal essential media, RPMI 1640). The solution should be supplemented with 1% penicillin and streptomycin.
Specimen Volume: 4-mm punch
Specimen Stability Information: Refrigerated (preferred)/Ambient
Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.
Specimen Type: Cultured fibroblasts
Container/Tube: T-25 flask
Specimen Volume: 2 Flasks
Collection Instructions: Submit confluent cultured fibroblast cells from a skin biopsy from another laboratory. Cultured cells from a prenatal specimen will not be accepted.
Specimen Stability Information: Ambient (preferred)/Refrigerated (<24 hours)
Additional Information: A separate culture charge will be assessed under CULFB / Fibroblast Culture for Biochemical or Molecular Testing. An additional 3 to 4 weeks is required to culture fibroblasts before genetic testing can occur.
Forms
1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available:
-Informed Consent for Genetic Testing (T576)
-Informed Consent for Genetic Testing (Spanish) (T826)
2. Molecular Genetics: Congenital Inherited Diseases Patient Information (T521)
3. Inborn Errors of Immunity, Autoimmunity, and Autoinflammatory Disease Patient Information
Secondary ID
619858Useful For
Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of an inborn error of immunity (IEI) associated with immune dysregulation or autoimmunity
Establishing a diagnosis of an IEI, allowing for appropriate management and surveillance for disease features based on the gene and/or variant involved
Identifying variants within genes known to be associated with immune dysregulation or autoimmunity, allowing for predictive testing of at-risk family members
Genetics Test Information
This test utilizes next-generation sequencing to detect single nucleotide and copy number variants in 30 genes associated with immune dysregulation and autoimmunity: AIRE, BACH2, CARD11, CASP10, CASP8, CD3G, CTLA4, DEF6, FADD, FASLG, FERMT1, FOXP3, IL10, IL10RA, IL10RB, IL2RA, IL2RB, ITCH, JAK1, LRBA, ORAI1, PEPD, PRKCD, RIPK1, STAT3, STAT5B, STIM1, TET2, TGFB1, and TPP2. See Targeted Genes and Methodology Details for Inborn Errors of Immunity with Immune Dysregulation and Autoimmunity Gene Panel and Method Description for additional details.
Identification of a disease-causing variant may assist with diagnosis, prognosis, clinical management, recurrence risk assessment, familial screening, and genetic counseling for inborn errors of immunity with immune dysregulation and autoimmunity.
Reflex Tests
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
CULFB | Fibroblast Culture for Genetic Test | Yes | No |
Testing Algorithm
For skin biopsy or cultured fibroblast specimens, fibroblast culture will be performed at an additional charge. If viable cells are not obtained, the client will be notified.
Special Instructions
Method Name
Sequence Capture and Targeted Next-Generation Sequencing (NGS) followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing
Reporting Name
Dysregulation/Autoimmune GenePanelSpecimen Type
VariesSpecimen Minimum Volume
Blood: 1 mL; Skin biopsy or cultured fibroblasts: See Specimen Required
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Varies | Varies |
Reject Due To
All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.Clinical Information
Primary immunodeficiencies or inborn errors of immunity (IEI) were originally defined by an increased risk of infections. Now it is clear that these diseases can also present with autoimmunity, autoinflammation, atopy, lymphoproliferation or malignancy, and infections are not always the leading cause of morbidity and mortality. This gene panel includes IEI with presentations characterized by autoimmunity. Examples of conditions where this gene panel is useful include immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome and other regulatory T-cell (Treg) defects; autoimmune polyendocrinopathy with candidiasis and ectodermal dystrophy (APECED or APS-1); and lymphoproliferation, solid organ autoimmunity, recurrent infections associated with gain-of-function STAT3 defects.
The development of autoimmune diseases can be caused by the dysregulation of the immune system, leading to defects in regulatory mechanisms that normally control the immune response. Thymic selection is critical for T-cell development and includes positive and negative selection of the maturing T cells. The positive selection ensures that mature T cells can recognize antigen-presenting molecules and thus carry out their function, whereas the negative selection eliminates developing T cells that are strongly autoreactive, including T cells directed against tissue-restricted antigens. The autoimmune regulator (AIRE) is responsible for intrathymic presentation of tissue-restricted antigens that would otherwise not be expressed in the thymus, and their absence in the thymus would allow the development of autoreactive T cells against these tissue-restricted antigens. Variants in the AIRE gene cause APECED because the self-antigens are not properly expressed in the thymus.
IPEX syndrome is characterized by systemic autoimmunity presenting in infancy. It typically presents with the triad of enteropathy (watery diarrhea), endocrinopathy (eg, insulin-dependent diabetes mellitus), and eczematous dermatitis. IPEX is caused by defects in the transcription factor FOXP3, which is required for the development of regulatory T cells. The regulatory (suppressive) actions of Tregs control autoimmunity. Tregs have different suppressive mechanisms, including cell contact-mediated cytotoxicity, sequestration of interleukin (IL)-2, and cytokine-mediated inhibition. Defects in the genes encoding these suppressive cytokines and cytokine receptors (eg, IL-10, IL-10 receptor alpha and beta, or transforming growth factor-beta [TGF-beta]) also lead to autoimmune manifestations. Cell-to-cell contact of membrane-bound molecules, such as CTLA-4, can transmit an inhibitory signal. In the absence of the inhibitory signal, CTLA-4 deficiency can manifest with recurrent infections, inflammatory bowel disease, in addition to autoimmunity. Increased (gain) of function in STAT3 signaling also decreases Treg numbers and function, leading to recurrent infections, lymphoproliferation, and, mainly, solid organ autoimmunity, such as thyroiditis, insulin-dependent diabetes mellitus, as well as autoimmune cytopenias.
Reference Values
An interpretive report will be provided.
Interpretation
All detected variants are evaluated according to American College of Medical Genetics and Genomics recommendations.(1) Variants are classified based on known, predicted, or possible pathogenicity and reported with interpretive comments detailing their potential or known significance.
Day(s) Performed
Varies
Report Available
28 to 42 daysSpecimen Retention Time
Whole blood: 2 weeks (if available); Extracted DNA: 3 months; Cultured fibroblasts, skin biopsy: 1 monthPerforming Laboratory
Mayo Clinic Laboratories in RochesterTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
81443
88233-Tissue culture, skin, solid tissue biopsy (if appropriate)
88240-Cryopreservation (if appropriate)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
IMMAU | Dysregulation/Autoimmune GenePanel | 103741-5 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
619859 | Test Description | 62364-5 |
619860 | Specimen | 31208-2 |
619861 | Source | 31208-2 |
619862 | Result Summary | 50397-9 |
619863 | Result | 82939-0 |
619864 | Interpretation | 69047-9 |
619865 | Additional Results | 82939-0 |
619866 | Resources | 99622-3 |
619867 | Additional Information | 48767-8 |
619868 | Method | 85069-3 |
619869 | Genes Analyzed | 82939-0 |
619870 | Disclaimer | 62364-5 |
619871 | Released By | 18771-6 |